Loading
A phase 2 trial of Enfortumab vedotin and Pembrolizumab in advanced solid tumours, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) is a phase 2 interventional study registered as NCT04225117 by Astellas Pharma Global Development, Inc., with 329 participants enrolled, started 2020-03-10 and due to reach its primary completion in 2025-02-25. Interventions recorded: enfortumab vedotin and pembrolizumab. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
329 enrolled.
95% CI 6.49 to 29.46; Figures from the ClinicalTrials.gov results section (first posted 2026-04-13), not from a publication · 95% CI 8.60 to 34.12 · 95% CI 0.11 to 21.95 · 95% CI 6.81 to 30.70 · 95% CI 12.59 to 38.77 · 95% CI 2.66 to 22.62 · 95% CI 8.19 to 32.71
Source95% CI 24.20 to 55.50; Figures from the ClinicalTrials.gov results section (first posted 2026-04-13), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessmentprimary | Cohort 1: HR+/HER2- Breast Cancer | 45 | 15.6% | - | - | link |
| Cohort 2: TNBC Cancer | 42 | 19% | ||||
| Cohort 3: Squamous NSCLC | 23 | 4.3% | ||||
| Cohort 4: Non-squamous NSCLC | 43 | 16.3% | ||||
| Cohort 5: Head and Neck Cancer | 46 | 23.9% | ||||
| Cohort 7: EAC | 42 | 9.5% | ||||
| Cohort 8: ESCC | 44 | 18.2% | ||||
| Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessmentprimary | Cohort 9: HNSCC | 41 | 39% | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pfizer (incl. Seagen), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Merck & Co. (MSD), Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.
Shares Astellas, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/